Study on the Pharmacokinetics and Bioequivalence of Mycophenolate Mofetil Soft Capsules / 中国药房

OBJECTIVE:To study the relative bioavailability and pharmacokinetics of Mycophenolate mofetil capsules vs.Mycophenolate mofetil soft capsules in healthy volunteers.METHODS:In double period randomized crossover study,20 healthy volunteers were given a single oral dose of trial capsule and reference capsule 4 pills(0.25 g per pill).The concentration of mycophenolate(MPA) was determined by HPLC.Pharmacokinetic parameters were calculated using DAs 2.0 software and the bioequivalence of 2 formulations were evaluated.RESULTS:Main pharmacokinetic parameters of trial capsule vs.reference capsule were as follows:AUC0→t:(69.95?14.13)?g?h?mL-1 vs.(66.95?19.05)?g?h?mL-1;AUC0→∞:(85.18?20.51)?g?h?mL-1 vs.(77.39?23.78) ?g?h?mL-1;Cmax:(31.26?13.09)?g?mL-1 vs.(31.90?14.45)?g?mL-1;tmax:(0.875?0.358)h vs.(0.775?0.291)h.The relative bioavailability of Mycophenolate mofetil soft capsules in 20 healthy volunteers was(109.6?26.9)%.CONCLUSION:Results of study indicated the 2 formulations are bioequivalent.

Relative Bioavailability and Bioequivalence of Valaciclovir Hydrochloride Tablets in Healthy Volunteers / 中国药房

OBJECTIVE:To study the pharmacokinetics and relative bioavailability of two kinds of preparations of valaciclovir hydrochloride.METHODS:This was a randomized two-way cross-over study.A total of 18 healthy volunteers were randomly assigned to receive single oral dose of test valaciclovir tablets(trial group) or reference valaciclovir tablets(control group),with the plasma aciclovir concentrations determined by HPLC,the pharmacokinetics parameters calculated and the relative bioavailability evaluated using 3p97 program.RESULTS:The main pharmacokinetic parameters test and reference valaciclovir hydrochloride tablets were as follows:AUC0～ 24:(12.85? 4.32) vs.(12.19? 4.63) ?g? h? mL-1;AUC0～ ∞:(14.65? 5.75) vs.(13.27? 5.03) ?g? h? mL-1;Cmax:(3.55? 0.92) vs.(3.71? 0.97) ?g? mL-1;tmax:(1.44? 0.43) h vs.(1.33? 0.37) h;t1/2:(6.23? 2.81) h and(4.55? 1.84) h.The relative bioavailability of the test valaciclovir tablets were(111.01? 23.52) %.CONCLUSION:The reference valaciclovir tablets and the test valaciclovir tablets were bioequivalent.

Comparative Study on in Vivo Pharmacokinetics of Gatifloxacin between Normal Canis Familiaris and Hepatic Injury Model / 中国药房

0.05) . CONCLUSION: Gatifloxacin has no significant influence on pharmacokinetics of the hepatic injury model group as compared with the normal group.

Use of Nootropics in Our Hospital During 2004～2006 / 中国药房

OBJECTIVE:To evaluate the status quo and tendency of the use of nootropics in our hospital.METHODS:The nootropics used in our hospital from 2004 to 2006 were analyzed statistically.RESULTS:The consumption sum of nootropics in our hospital increased year by year,2.03 times in 2005 and 1.46 times in 2006 respectively over their previous year.The consumption sum of Ginkgo biloba extract for nootropics took the lead from 2005 to 2006,over 60% of which were medical insurance drugs.CONCLUSION:Leading the list of nootropics in our hospital is plant amedica,with its consumption sum and DDDs showing the equal importance in drug control,suggesting the great market demand for nootropics.

How to Treat the Difference of Drug Prices between Used in Hospital and Retailed in Market / 中国药房

OBJECTEVE:To probe into the difference of drug prices between used in hospital and retailed in market.METHODS:Analysis the different reasons of drug price from drug quality assurance system,pharmaceutical care,drug using structure system and function mechanism.RESULTS&CONCLUSION:It's rational that the drug prices used in hospital high_ er than in retailed market.It's pratical and realistic attitude to the fact that the same drug has different prices in the medical market.